{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106236","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.152916+00:00","generated_at":"2026-05-17T15:23:27.185392+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm Q2 net loss $37.3M; explores financing/strategic alternatives; cash $52M","bullets":["Total revenue $37.9M; US XPOVIO net product revenue $29.7M (+6% YoY). Net loss $37.3M ($4.32/share).","FY2025 total revenue guidance reaffirmed $140-155M; US XPOVIO revenue guidance updated to $110-120M.","Cash, equivalents & investments $52M at June 30; expects liquidity to fund ops into Jan 2026 excluding $24.5M note maturity Oct 2025.","Phase 3 SENTRY (myelofibrosis) enrollment screening close this week; top-line data expected March 2026.","Engaged Centerview Partners to explore financing and strategic alternatives to extend cash runway and maximize value."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106236","json":"https://secwatch.observer/filing/0000950170-25-106236.json","markdown":"https://secwatch.observer/filing/0000950170-25-106236.md","text":"https://secwatch.observer/filing/0000950170-25-106236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025106236/0000950170-25-106236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025106236/kpti-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:23:27.185392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}